Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × Cancer Related Cognitive Decline × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 291 Leukemia, Myeloid, Acute 236 Multiple Myeloma 208 Carcinoma, Non-Small-Cell Lung 197 Prostatic Neoplasms 189 Neoplasms 178 Lymphoma 174 Melanoma 165 Colorectal Neoplasms 165 Leukemia 160 Precursor Cell Lymphoblastic Leukemia-Lymphoma 144 Pancreatic Neoplasms 143 Recurrence 135 Lung Neoplasms 134 Glioblastoma 123 Neoplasm Metastasis 122 Lymphoma, Non-Hodgkin 116 Ovarian Neoplasms 113 Leukemia, Lymphocytic, Chronic, B-Cell 105 Myelodysplastic Syndromes 104 Lymphoma, Large B-Cell, Diffuse 97 Lymphoma, Mantle-Cell 94 Carcinoma, Hepatocellular 90 Lymphoma, Follicular 85 Stomach Neoplasms 84 Brain Neoplasms 84 Hodgkin Disease 82 Carcinoma, Renal Cell 80 Sarcoma 75 Burkitt Lymphoma 66

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡